CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
08/05/2023
Voltar para busca
Dado oficial do USPTO
PRECISION BIOSCIENCES
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
PRECISION BIOSCIENCES
ST13
US500000097117501Classe
1, 5, 42, 44
Pedido
97117501
Registro
7034223
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
26
Atualização mais recente
08/05/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42, 44
Data de depósito
10/11/2021
Data de registro
25/04/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
25/04/2023
Última transação
08/05/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Primeiro uso
11/02/2008
Primeiro uso no comércio
11/02/2008
Código do desenho
4
Tipo de titular
03
Localização do titular
Durham, NC
Examinador
BUSH, KAREN
Unidade examinadora
L80
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Precision BioSciences, Inc.
Representantes
Eva Gullick Frongello Parker Poe Adams & Bernstein LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
genome editing reagents for research purposes; Chemicalbiochemicalbiotechnological products intended for industryagriculturehorticulturepolypeptides for in vivo and in vitro genetic engineeringnatural and engineered meganucleases and endonucleasesnucleic acid vectorsmolecular scissors; chemicalbiochemicalbiotechnological and bacteriological products intended for research laboratories and control laboratoriespolypeptides for in vivo and in vitro genetic engineering; Biochemicals and biologicsengineered proteins for gene regulationgenome engineeringgene modulationtranscriptional regulationtranscriptional modulationgene modificationgene correctionall for use in scientific researchpharmaceutical researchagricultural biotechnologydiagnosticsindustrial biotechnology; engineered proteins for use in scientific research and analysis relating to genetic diseasesgene therapycell therapy; biochemicals and biologicsengineered nucleic acidsviral vectorsnon-viral vectorsgene therapy vectorsgene editing vectorsgenetically modified cellsengineered proteins for multiplexed gene editingmRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cellsantibody preparationsCAR T-cell preparationsT-cell preparationsB-cell preparationsTreg preparationsNK cell preparationsall for use in scientific research and analysis and diagno
Classe 5
pharmaceutical preparationscell therapy products utilizing t-cell therapy for use in treating disease; cell-based immunotherapeutic treatment by way of genetically modified cells for use in human therapeutics and the treatment of cancer; pharmaceuticals for the treatment of cancer; pharmaceutical preparations in the nature of genetically modified cellsgenetically modified immune cells for use in human therapeutics and in the treatment of cancer; pharmaceutical and biological preparations based on genegenome and cellular editingmodulationmodificationengineeringregulationrepair and therapy for use in human therapeuticstherapeutic pharmaceuticals developed through genome modifications for the treatment of cardiovascularcentral nervous systemendocrinegastrointestinalgenetic immunologicalinfectiousinflammatorymenopausalmetabolicautoimmunemusculoskeletalneurologicalophthalmologicalpsychiatricrespiratoryurogenitalurologicalhematologic and viral diseases and disorders; pharmaceutical preparationstherapeutic pharmaceuticals developed through genome modifications for the treatment of erectile dysfunctionsexual dysfunctioncancerpain and diabetes; pharmaceutical preparationstherapeutic pharmaceuticals developed through genome modificationsantifungal preparationsdermatological preparationssmoking cessation preparations and tissue repair preparations; engineered nucleic acidsviral vectorsnon-viral vectorsgene therapy vectorsgene editing vectorsgenetically modified cellsengineered proteins for multiplexed gene editingmRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cellsantibody preparationsCAR T-cell preparationsT-cell preparationsB-cell preparationsTreg preparationsNK cell preparationsall for clinical usemedical useclinical laboratory usemedical laboratory use
Classe 42
research in the fields of genome editinggene editinggenome engineeringgene modulationtranscriptional regulationtranscriptional modulationgenetic diseasegene therapy and cell therapy; pharmaceutical research and development services; Scientific research; scientific research in geneticmedicalpharmaceutical and veterinary fields; scientific research in chemistrybiologybiochemistrymolecular biologybacteriology; scientific analysis in the field of immunotherapy; scientific research in the field of cellular immunotherapy utilizing chimeric antigen receptor t cells for use in treating cancer
Classe 44
Medical servicescellular immunotherapy treatments utilizing chimeric antigen receptor t cells for use in treating diseasethe treatment of cancer
Publicações
Histórico de despachos e eventos da marca no USPTO.
26 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/05/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/05/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/05/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
08/05/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
25/04/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
25/04/2023
ATRV
ATTORNEY REVIEW COMPLETED
06/03/2023
LOPR
LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN
06/03/2023
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
06/03/2023
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
01/03/2023
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
18/01/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
20/12/2022
PUBO
PUBLISHED FOR OPPOSITION
20/12/2022
LOPT
LETTER OF PROTEST EVIDENCE FORWARDED
15/12/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
30/11/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/11/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/11/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/11/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/11/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/05/2022
GNRT
NON-FINAL ACTION E-MAILED
12/05/2022
CNRT
NON-FINAL ACTION WRITTEN
12/05/2022
DOCK
ASSIGNED TO EXAMINER
10/05/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
17/11/2021
NWAP
NEW APPLICATION ENTERED
13/11/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PRECISION BIOSCIENCES ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.